Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis Licenses CureDM's Early-Stage Diabetes Compound To Bolster Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

Privately-held CureDM could receive up to $335 million in payments, plus sales royalties, from Sanofi-Aventis.

You may also be interested in...



A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects

Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.

Sanofi-Aventis Takes Rights to Metabolex's Diabetes Compound

As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.

Sanofi-Aventis Takes Rights to Metabolex's Diabetes Compound

As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel